MDACC Study No:2010-0303 ( NCT No: NCT01167166)
Title:A Phase 1/2, Single Arm Study to Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice-daily Oral Capsules Given Continuously in Patients with Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms
Principal Investigator:Jorge Cortes
Treatment Agent:ON 01910.Na
Study Status:Terminated
Study Description:The goal of the Phase I portion of this clinical research study is to check the
safety of a drug called Rigosertib (ON 01910.Na) when given to patients with
AML, ALL, or an MPN.

The goal of the Phase II portion of this study is to learn if rigosertib can
help to control the disease in patients with AML, ALL, or an MPN. The safety
of this drug will continue to be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:ON 01910.Na
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Onconova Therapeutics Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults